A startup that aims to make treating diseases more personalized just raised another $110 million. Tempus, which was started by Groupon founder Eric Lefkofsky, aims to use data to find better cancer treatments for patients, using both clinical data — information about which medications patients have taken and how they responded to them — and genetic data from the tumors of cancer patients. The company announced on Wednesday that it has raised $110 million at a $2 billion valuation, bringing its total funding to $320 million. In 2018 alone, the company has raised $190 million. The funding came from investors including Baillie Gifford, T. Rowe Price, Revolution Growth, New Enterprise Associates, and previous investors in the company. Chicago-based Tempus got its start in 2015, and in the last three years has rocketed into unicorn territory. The startup runs a lab that's able to sequence tumor genetics — as well as the genes they're born with — to see what mutations could be impacting an individual's cancer. At the same time, Tempus sorts through clinical data from doctors, hospitals, and studies to standardize the information and analyze for patterns. It's similar to the work of two other prominent companies that were both recently acquired by pharma giant Roche: Flatiron Health, which focuses on collecting clinical data about cancer, and Foundation Medicine, which is centered around cancer genetics. Tempus said in a press release that the new funding would be used to expand its technology into new treatment areas beyond cancer, as well as to grow geographically. Tempus said its platform currently reaches one of every four cancer patients in the US.
Touch , a tech start - up set up by Groupon founder Eric Schmidt , has announced that is has raised $ 110 m for its personalised cancer treatments . Founded in 2015 , the investment brings the company 's total funding to $ 320 m , along with a valuation of $ 2bn . The funding came from new investors , including Baillie ##u , T. Rowe Price , Revolution Growth and New Enterprise Associates , as well as existing stakeholders . In a press release , Tempus said the new funding would be used to expand its business into new treatment areas , beyond cancer , as well as to grow geographically .